In a report released yesterday, Nick Abbott from Wells Fargo reiterated a Buy rating on Zymeworks (ZYME – Research Report), with a price target of $45.00. The company's shares closed last Tuesday at $7.15, close to its 52-week low of $4.56. According to TipRanks.com, Abbott has 0 stars on 0-5 stars ranking scale with an average return of -46.2% and a 0.0% success rate. Abbott covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Arcturus Therapeutics, and Alaunos Therapeutics. Currently, the analyst consensus on Zymeworks is a Strong Buy with an average price target of $23.20, which is a 256.9% upside from current levels.
https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-zymeworks-zyme?utm_source=advfn.com&utm_medium=referral
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Zymeworks Charts.
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Zymeworks Charts.